IP Library › Granted Patent US 8,039,622
Granted Patent B2
US 8,039,622 · App. 12/615,407 · Granted Oct 18, 2011

Melanocortin receptor agonists

Assignee: LG Life Sciences Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,039,622
App. No.
12/615,407
Granted
Oct 18, 2011
Kind
B2
Abstract

The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Claims (1)

1. (2S)—N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidin-3-yl]carbonyl}-5-[(4-methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl}-N-(cis-4-methylcyclohexyl)tetrahydrofuran-2-carboxamide or a salt thereof.

Assignments (2)
MERGER Recorded Sep 2, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043475/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2009
From: LEE, KOO; LEE, SANG DAE; MOON, SANG PIL; AHN, IN AE; CHOI, SUNG PIL; LEE, HYUN HO; SHIM, DONG SUP; CHUNG, SOO YONG; LEE, HYUN MIN
To: LG LIFE SCIENCES LTD.
Reel/Frame 023592/0546 →
Priority Claims (1)
KR 10-2008-0112403 · Nov 12, 2008 · national
Continuity (1)
Related Publication 20100120783A1 · May 13, 2010